At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LIPO Lipella Pharmaceuticals Inc
Post-Market Trading 01-08 19:08:23 EST
3.17
-0.01
-0.31%
盘后3.17
+0.000.00%
19:03 EST
High3.37
Low2.92
Vol238.69K
Open3.12
D1 Closing3.18
Amplitude13.99%
Mkt Cap3.83M
Tradable Cap2.71M
Total Shares1.21M
T/O754.45K
T/O Rate27.96%
Tradable Shares853.80K
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Lipella Pharmaceuticals announces publication in CUREUS
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.